Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

Angela Bellini,Ulrike Pötschger,Virginie Bernard,Eve Lapouble,Sylvain Baulande,Peter F. Ambros,Nathalie Auger,Klaus Beiske,Marie Bernkopf,David R. Betts,Jaydutt Bhalshankar,Nick Bown,Katleen De Preter,Nathalie Clement,Valérie Combaret,Jaime Font de Mora,Sally L. George,Irene Jiménez,Marta Jeison,Bárbara Marques,Tommy Martinsson,Katia Mazzocco,Martina Morini,Annick Mühlethaler-Mottet,Rosa Noguera,Gaëlle Pierron,Maria Rossing,Sabine Taschner-Mandl,Nadine Van Roy,Ales Vicha,Louis Chesler,Walentyna Balwierz,Victoria Castel,Martin Elliott,Per Kogner,Genevieve Laureys,Roberto Luksch,Josef Malis,Maja Popovic-Beck,Shifra Ash,Olivier Delattre,Dominique Valteau-Couanet,Deborah A. Tweddle,Ruth Ladenstein,Gudrun Schleiermacher

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

2021

PURPOSEIn neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in hig...

Keywords:

high risk neuroblastoma
ALK receptor tyrosine kinase
Medicine
Cancer research
Point mutation
Neuroblastoma
Text mining

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations